New research reveals statins may significantly improve survival for people with CLL - even when receiving modern targeted treatments. 👏 More research is needed, but this is a major step towards potentially repurposing common drugs in blood cancer care. scienmag.com/statin-therapy…

📢 We’re calling on the Government to commit to doubling the five-year survival for acute myeloid leukaemia (AML) from 22% to 44%. Will you join us? Just five days left to share your experiences and help shape the Government’s National Cancer Plan: leukaemiauk.org.uk/stories/the-na…

We're excited to see the launch of the TARGET study, co-led by Bill Grey, to tackle AML relapse by targeting chemo-resistant stem cells. This could mean oral treatments at home, fewer side effects, and safer options for all. 🧡 Read more: leedsth.nhs.uk/news/new-resea…

A HUGE good luck to our fantastic team taking on the #LondonMarathon today! We’ll be there giving you the biggest cheers (just look out for the crazy bunch in orange!) 🧡🔶🍊 Go #TeamLUK - you’ve got this! 👊 #LondonMarathon2025

Fantastic news! For the first time, there could be a reliable way to screen for early signs of relapse in leukaemia. This simple test will give doctors time to act while patients are still well, leading to more treatment options & better survival rates. 👏 independent.co.uk/news/health/bl…

Big breakthrough for adult B-ALL patients in the UK! A new CAR-T cell therapy, Aucatzyl (obecabtagene autoleucel), has been conditionally approved by the MHRA. If approved by NICE, it could significantly improve survival outcomes. 👏 Read more: gov.uk/government/new…

We were delighted to attend this year’s @‌BritSocHaem conference, learning the latest about clinical management of leukaemia and unmet needs. We’ll continue collaborating with the haematology community to improve diagnosis, treatment & care for those affected by leukaemia. #BSH25

Exciting early results from the SENTI-202 trial, a first-in-class CAR NK therapy for AML: off-the-shelf, engineered to target cancer while sparing healthy cells. With early remissions and a strong safety profile, it offers real hope for a game-changing AML treatment.

A new study, featuring our funded researcher Bill Grey, reveals that age-related blood mutations can worsen outcomes in lung and other solid cancers, highlighting a key link between blood and tumour evolution. Read more 👇 nejm.org/doi/10.1056/NE…~

Visit your doctor if experiencing symptoms, as ignoring them can lead to delays, which could be deadly for leukaemia patients. ⚠️ We support the report’s call for the NHS to become an “early intervention service” as early diagnosis saves lives. theguardian.com/society/2025/m…

We’re pleased that the NHS is trialling advanced screening tools to detect early signs of cancer. A simple blood test is one of the few ways to detect leukaemia early, so regular testing could be life-saving. 🧡 the-independent.com/life-style/hea…

We're incredibly proud to have backed this groundbreaking study by our funded researcher Kostas Tzelepis and team! It could pave the way for more precise, and less toxic, treatments for AML patients facing relapse. 👏 express.co.uk/news/uk/205335…

Have you been diagnosed with chronic lymphocytic leukaemia (CLL)? We’re gathering patient experiences to support the evaluation of three new CLL treatments by NICE. Share your views by 23rd May and help shape future care for people with CLL: forms.office.com/e/bZkkiYEirD

We are delighted to announce further funding for ground-breaking leukaemia research through our 2025 Project Grants! Applications will open on 2nd June 2025. Please share amongst your research networks! 🔬 Find out more and apply 👉 leukaemiauk.org.uk/research-and-a…

Good luck to our incredible team of ONE-HUNDRED-AND-EIGHTYYYYY 🎯 runners in the Hackney Half Marathon today - our biggest team EVER! We'll be giving you the biggest cheers in the crowd. Let’s go #TeamLUK! 🧡 HACKNEY MOVES #HackneyHalfMarathon #HackneyHalf

Over the past two years, this brilliant group of delegates and mentors have worked together on the design and delivery of blood cancer clinical trials. We’re proud to support these workshops with the DIDACT Foundation and look forward to seeing which new trials result. 🔬🧪

A team led by two of our funded scientists has developed a promising, potentially less toxic treatment for B-ALL. This new approach, combining two oral drugs, could be a step forward in offering kinder, more targeted treatments for B-ALL 🙏 cam.ac.uk/stories/B-ALL-…

Our funded researcher Eman Khatib-Massalha is making major strides in understanding myeloproliferative neoplasms (MPNs) 👏 Her team uncovered why certain immune cells aren’t properly cleared away in people with MPNs, paving the way for new treatment approaches. ashpublications.org/blood/article/…